GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Apollo Endosurgery Inc (NAS:APEN) » Definitions » Debt-to-EBITDA

Apollo Endosurgery (Apollo Endosurgery) Debt-to-EBITDA : -1.89 (As of Dec. 2022)


View and export this data going back to 2007. Start your Free Trial

What is Apollo Endosurgery Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Apollo Endosurgery's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $20.26 Mil. Apollo Endosurgery's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $36.81 Mil. Apollo Endosurgery's annualized EBITDA for the quarter that ended in Dec. 2022 was $-30.28 Mil. Apollo Endosurgery's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2022 was -1.88.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Apollo Endosurgery's Debt-to-EBITDA or its related term are showing as below:

APEN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.29   Med: -2.83   Max: -0.66
Current: -1.81

During the past 13 years, the highest Debt-to-EBITDA Ratio of Apollo Endosurgery was -0.66. The lowest was -4.29. And the median was -2.83.

APEN's Debt-to-EBITDA is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.24 vs APEN: -1.81

Apollo Endosurgery Debt-to-EBITDA Historical Data

The historical data trend for Apollo Endosurgery's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollo Endosurgery Debt-to-EBITDA Chart

Apollo Endosurgery Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.66 -2.83 -4.29 -4.13 -1.81

Apollo Endosurgery Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.47 -2.15 -1.60 -1.45 -1.89

Competitive Comparison of Apollo Endosurgery's Debt-to-EBITDA

For the Medical Devices subindustry, Apollo Endosurgery's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollo Endosurgery's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Apollo Endosurgery's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Apollo Endosurgery's Debt-to-EBITDA falls into.



Apollo Endosurgery Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Apollo Endosurgery's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(20.256 + 36.809) / -31.618
=-1.80

Apollo Endosurgery's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(20.256 + 36.809) / -30.28
=-1.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2022) EBITDA data.


Apollo Endosurgery  (NAS:APEN) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Apollo Endosurgery Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Apollo Endosurgery's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollo Endosurgery (Apollo Endosurgery) Business Description

Traded in Other Exchanges
N/A
Address
1120 S. Capital of Texas Highway, Building 1, Suite 300, Austin, TX, USA, 78746
Apollo Endosurgery Inc is active in the healthcare sector based in the United States. As a developer of medical devices, Apollo focuses on addressing obesity, as well as other gastrointestinal disorders. Its products are used by general surgeons, bariatric surgeons and gastroenterologists in a variety of settings to provide interventional therapy to patients who suffer from obesity. The company's products include the OverStitch Endoscopic Suturing System, X-Tack Endoscopic HeliX Tacking System, and the Orbera Intragastric Balloon System.
Executives
Antal Rohit Desai 10 percent owner C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065
Sharon O'keefe director C/O VOCERA COMMUNICATIONS, INC., 525 RACE STREET, SAN JOSE CA 95126
Jeannette Bankes director ONE ALLENTOWN PARKWAY, ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Jeffrey G. Black officer: Chief Financial Officer 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Mike Gutteridge officer: VP, Int'l Sales and Marketing 1120 S. CAPITAL OF TEXAS HIGHWAY, BUILDING 1, SUITE #300, AUSTIN TX 78746
Cpmg Inc 10 percent owner 4215 WEST LOVERS LANE, SUITE 100, DALLAS TX 75209
Mcgaughy R Kent Jr director, 10 percent owner 500 CRESCENT COURT, SUITE 250, DALLAS TX 75201
Chas Mckhann director, officer: President and CEO 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
David Pacitti director C/O APOLLO ENDOSURGERY, INC., 1120 S., CAPITAL OF TEXAS HWY, BLDG. 1, SUITE 300, AUSTIN TX 78746
John R Barr director VI TECHNOLOGIES INC, 134 COOLIDGE AVENUE, WATERTOWN MA 02472
Neil Gagnon 10 percent owner 1370 AVENUE OF THE AMERICAS, 24TH FLOOR, NEW YORK NY 10019
Traweek James W Jr 10 percent owner 2000 MCKINNEY AVE, SUITE 2125, DALLAS TX 75201
Todd Newton director, officer: Chief Executive Officer 1120 S CAPITAL OF TX HWY, BUILDING ONE, STE 300, AUSTIN TX 78746
Stonepine Capital, L.p. 10 percent owner 919 NW BOND STREET, SUITE 204, BEND OR 97703
Matthew S Crawford director, 10 percent owner 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746

Apollo Endosurgery (Apollo Endosurgery) Headlines

From GuruFocus

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates APEN, HZNP, MLVF, TCFC

By Stock market mentor Stock market mentor 01-05-2023